In order to find the lowest dose needed to have a significant effect on CLL cells in vivo and to test the effect of MSI2 inhibition on early hematopoietic cells, we next treated recipient animals with the previous low Ro 08-2750 dose, 7.0 mg/kg, and with a lower dose 1.4 mg/kg. Here, MSI2 is linked to B-cell chronic lymphocytic leukemia.